1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>France

Servier Denies Deceit As French Mediator Trial Begins

Company and regulator both in the dock over failure to act

 
• By Ian Schofield

A trial has begun in France to investigate the roles of the French firm Servier and the former drug regulator AFSSAPS in the Mediator scandal, where an amphetamine-like drug was kept on the market despite mounting evidence of its cardiac side-effects.

Side effects
A French trial is looking into the fatal side-effects of diabetes drug Mediator

As a French trial begins to ascertain who was responsible for the decade-old Mediator scandal, Servier has insisted it did not deceive regulators about the fatal cardiac side-effects of the amphetamine like drug, which was approved for weight loss in diabetics but was widely prescribed as a diet aid for healthy individuals.

Asserting that responsibility for the scandal had to be shared with the regulators, a spokesman for Servier also denied that the company had taken steps to delay the trial, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from France

More from Europe

Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

 
• By Vibha Sharma

A report by the European pharmaceutical industry criticizes the EU’s clinical trials framework, highlighting regulatory fragmentation, inefficiencies and the need for targeted reforms.

EU Moment Of Truth For Obe-Cel And 10 Other New Medicines

 
• By Neena Brizmohun

Autolus’s CAR T therapy obe-cel is among the medicines that are this week due for an opinion by the European Medicines Agency on whether they should be marketed in the EU.

Blenrep’s Revival Gains Steam: EMA Decision Imminent As Japan Approves New Regimen

 
• By Neena Brizmohun

The European Medicines Agency is due to decide whether GSK’s previously approved multiple myeloma drug that was withdrawn from the market in 2022 should be approved again for use in combination with BorDex or PomDex. Meanwhile, Japan today became the second major regulator to approve the Blenrep combinations.